AGL 40.10 Increased By ▲ 0.10 (0.25%)
AIRLINK 130.70 Increased By ▲ 1.17 (0.9%)
BOP 6.79 Increased By ▲ 0.11 (1.65%)
CNERGY 4.60 Decreased By ▼ -0.03 (-0.65%)
DCL 8.97 Increased By ▲ 0.03 (0.34%)
DFML 43.02 Increased By ▲ 1.33 (3.19%)
DGKC 84.15 Increased By ▲ 0.38 (0.45%)
FCCL 33.04 Increased By ▲ 0.27 (0.82%)
FFBL 78.07 Increased By ▲ 2.60 (3.45%)
FFL 11.91 Increased By ▲ 0.44 (3.84%)
HUBC 110.83 Increased By ▲ 0.28 (0.25%)
HUMNL 14.56 No Change ▼ 0.00 (0%)
KEL 5.62 Increased By ▲ 0.23 (4.27%)
KOSM 8.26 Decreased By ▼ -0.14 (-1.67%)
MLCF 39.83 Increased By ▲ 0.04 (0.1%)
NBP 60.80 Increased By ▲ 0.51 (0.85%)
OGDC 200.05 Increased By ▲ 0.39 (0.2%)
PAEL 26.55 Decreased By ▼ -0.10 (-0.38%)
PIBTL 7.80 Increased By ▲ 0.14 (1.83%)
PPL 160.59 Increased By ▲ 2.67 (1.69%)
PRL 26.75 Increased By ▲ 0.02 (0.07%)
PTC 18.60 Increased By ▲ 0.14 (0.76%)
SEARL 83.02 Increased By ▲ 0.58 (0.7%)
TELE 8.23 Decreased By ▼ -0.08 (-0.96%)
TOMCL 34.40 Decreased By ▼ -0.11 (-0.32%)
TPLP 9.10 Increased By ▲ 0.04 (0.44%)
TREET 17.00 Decreased By ▼ -0.47 (-2.69%)
TRG 60.30 Decreased By ▼ -1.02 (-1.66%)
UNITY 27.81 Increased By ▲ 0.38 (1.39%)
WTL 1.42 Increased By ▲ 0.04 (2.9%)
BR100 10,564 Increased By 156.9 (1.51%)
BR30 31,945 Increased By 232 (0.73%)
KSE100 98,633 Increased By 1305.1 (1.34%)
KSE30 30,710 Increased By 517.4 (1.71%)
World

UK health minister says data on Pfizer vaccine supports shift to 12-week dosing schedule

  • Around 89% efficacy comes from between days 14 and days 21 after the first dose," Hancock told lawmakers.
Published January 21, 2021

LONDON: Data supports Britain's decision to move to a 12-week dosing schedule for Pfizer's COVID vaccine, health minister Matt Hancock said on Thursday, adding details on efficacy gathered during the rollout would be published as soon as possible.

"Around 89% efficacy comes from between days 14 and days 21 after the first dose," Hancock told lawmakers, saying he had reviewed the data, and that it supported the decision to move to a 12-week schedule between doses.

"We're looking at this data, and in fact we're measuring the efficacy here at home for those who've been vaccinated, by matching the data between those who've been vaccinated and those who test positive. And we're monitoring that and we will publish that data as soon as it is clinically valid."

Comments

Comments are closed.